More biosimilar approvals for Celltrion as it closes in on the US market
This article was originally published in Scrip
Executive Summary
Two major biosimilar product approvals for Celltrion, in South Korea and Canada, will serve to consolidate the South Korean firm's already strong competitive position in the biosimilar MAb space as it moves towards a filing in the key US market.